BioSpace News Archive

Inotiv estimates that the net proceeds from the offering will be approximately $120.5 million (or approximately $135.1 million if the initial purchaser fully exercises its option to purchase additional notes), after deducting the initial purchaser’s discounts and commissions and estimated offering expenses.

Illumina, Inc. (NASDAQ:ILMN) today announced that Bob Ragusa has been appointed as Chief Executive Officer of GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, effective immediately.

MiNK Therapeutics, Inc. (“MiNK”), a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the pricing of its initial public offering of 3,333,334 shares of common stock at a public offering price of $12.00 per share.